# A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

> **NCT03207867** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 315 (actual)

## Conditions studied

- NSCLC, Non Small Cell Lung Cancer
- RCC, Renal Cell Cancer
- Pancreatic Cancer
- Urothelial Cancer
- Head and Neck Cancer
- DLBCL, Diffused Large B Cell Lymphoma
- MSS, Microsatellite Stable Colon Cancer
- TNBC, Triple Negative Breast Cancer
- Melanoma
- mCRPC, Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** NIR178
- **DRUG:** PDR001

## Key facts

- **NCT ID:** NCT03207867
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-28
- **Primary completion:** 2023-02-13
- **Final completion:** 2023-02-14
- **Target enrollment:** 315 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03207867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03207867, "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03207867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*